Sterile Medical Devices Are Not Low-Risk in Mexico

1. Key takeaways

In Mexico, all sterile medical devices are outside the low-risk track, and none of the reliefs of the 2025 low-risk agreement applies to them. No matter how simple the product design is, if the product is intended to be provided in a sterile state, it must return to the regular risk classification system and go through sanitary registration; it cannot claim exemption from registration under Annex II. The rule operates as a gate at the front of the analysis: sterility status is asked before the class, before the annex and before the pathway, because the answer decides whether the low-risk conversation happens at all. Companies that discover the exclusion late — after preparing an exemption-based import plan or after contracting distribution on the assumption of no registration — face a compressed timeline to prepare a registration dossier. Making sterility status a mandatory field in the product intake questionnaire is the cheapest way to prevent that scenario.

2. Legal basis

The exclusion rests on a chain of instruments: the agreement itself states the exclusion, the pharmacopeial supplement encodes it as a condition of low-risk identification, and the manufacturing standard governs sterilization requirements once the regular route applies.

Each source adds one step to the analysis: the agreement removes the shortcut, rule 23 explains why the shortcut is unavailable, the RIS articles define where the product lands instead, and the NOM defines the technical work that follows. A file that shows all four steps reads cleanly under review.

It is worth noting how the exclusion interacts with portfolio segmentation. In a mixed portfolio, the sterile subset follows a completely different project shape from the non-sterile subset: different evidence sets, different timelines, different fee expectations and different labeling work. Attempting to run both subsets through one template process is a recurring source of missed steps. Splitting the project plan by sterility status at the very beginning, rather than by product line or brand, aligns the plan with the way the regulation itself partitions the obligations.

3. Expert insights

Insight 1: Sterility is an exclusion condition of low-risk identification. Among the low-risk conditions listed in rule 23 of the FEUM supplement is the requirement that the intended use does not call for sterile provision. This condition is a hard gate: if it is not met, the device is excluded and there is no need to assess the remaining conditions. The design of the rule matters operationally, because it means the sterility question can and should be answered first, before any investment in the rest of the low-risk argument. A checklist that starts with sterility status will terminate quickly and correctly for sterile products, saving analysis effort for the products where the low-risk track is genuinely available.

Insight 2: Sterility pulls the product back into the regular evidence chain. Once low-risk treatment is unavailable, the device is classified under RIS Articles 83 and 83 Bis, and evidence is prepared according to the class: sterilization method, sterilization validation, packaging and shelf-life arguments, among others. The difference in evidence depth between Class II and Class III is substantial. Planning this evidence early, in parallel with the classification decision, avoids the common failure mode of reaching dossier assembly before realizing that sterilization validation documentation needs months of preparation work upstream in the quality system.

Insight 3: A change in sterile status is itself a change. Moving a product from non-sterile to sterile provision, or changing the sterilization method, is not an adjustment a company can absorb internally; it must be handled through the amendment (Modificación) procedure and may also trigger a labeling revision. Treating such a shift as a minor internal matter leaves the registration out of line with the product actually on the market, which is exactly the kind of discrepancy that verification activities and border checks are designed to catch. The amendment should be approved before the modified product ships.

Insight 4: The labeling symbols requirement stacks on top. Annex A of the new labeling standard NOM-137-SSA1-2025 incorporates 70 standardized symbols, including symbols related to sterilization methods. Once the new standard takes effect in May 2027, sterile devices must present their sterilization markings under the new symbol system. Because label artwork changes feed into registration amendments, the symbol migration should be planned together with the amendment calendar rather than as a separate labeling project.

4. Practical recommendations

1. Use whether the product is provided sterile as the first screening criterion in the product list, and route sterile products into the regular pathway from the start.
2. Organize sterilization validation documentation around the ISO 11135 and ISO 11137 frameworks, and include a method and validation summary in the dossier.
3. When sterile status or sterilization method changes, complete the amendment before release; do not adjust the product informally while it remains in its registered state.
4. Back-plan label redesign and registration amendments from the NOM-137-SSA1-2025 effective point (360 calendar days after publication, approximately 2027-05-14).
5. For simple non-sterile passive consumables claiming low-risk status, first confirm the item number in the Annex I or Annex II lists before relying on it.

5. Verification checklist

• □ First-level screening completed on whether the product is provided sterile
• □ No Annex II exemption claimed for sterile products
• □ Sterilization method and validation documentation included in the dossier
• □ Changes in sterile status or sterilization method processed through the amendment procedure
• □ Label sterilization symbols scheduled against Annex A of NOM-137-SSA1-2025

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com